UroGen Pharma (URGN) FCF Margin (2017 - 2026)
UroGen Pharma's (URGN) quarterly FCF Margin came in at 93.5% in Q1 2026, up 11291.0% YoY from N/an in Q1 2025, and up 3.67% on a QoQ basis from 97.07% in Q4 2025.
UroGen Pharma (URGN) FCF Margin (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of FCF Margin data on file, last reported at 93.5% in Q1 2026.
- Quarterly FCF Margin rose 11291.0% year-over-year to 93.5% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 123.04% (down 730.0% YoY) and the FY2025 annual result came in at 152.13%, down 4668.0% from the prior year.
- FCF Margin rose to 93.5% in Q1 2026, from 97.07% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 55.18% in Q4 2023 to a low of 206.41% in Q1 2025.
- A 5-year average of 124.46% and a median of 112.87% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin surged 19176 bps — and 2025, when it tumbled 6693 bps.
- Tracing URGN's FCF Margin over 5 years: stood at 121.72% in 2022, then soared by 55 bps to 55.18% in 2023, then retreated by 2 bps to 56.33% in 2024, then slumped by 72 bps to 97.07% in 2025, then climbed by 4 bps to 93.5% in 2026.
- The last three FCF Margin figures came in at 93.5% (Q1 2026), 97.07% (Q4 2025), and 175.49% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | -47.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.30% |
| Mar 31, 2026 | -93.50% |
| Dec 31, 2025 | -97.07% |
| Sep 30, 2025 | -175.49% |
| Jun 30, 2025 | -166.24% |
| Mar 31, 2025 | -206.41% |
| Dec 31, 2024 | -56.33% |
| Sep 30, 2024 | -108.56% |
| Jun 30, 2024 | -106.75% |
| Mar 31, 2024 | -163.97% |
| Dec 31, 2023 | -55.18% |
| Sep 30, 2023 | -79.28% |
| Jun 30, 2023 | -94.28% |
| Mar 31, 2023 | -152.56% |
| Dec 31, 2022 | -121.72% |
| Sep 30, 2022 | -112.87% |
| Jun 30, 2022 | -147.40% |
| Mar 31, 2022 | -178.16% |
| Dec 31, 2021 | -120.67% |
| Sep 30, 2021 | -167.59% |